SCI Abstract

search
+
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a poor 5‑year survival ...
mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications
mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications
Polycythemia vera (PV) is a myeloproliferative neoplasm primarily driven by mutations in the JAK2 gene, most notably the V...
Rare case of human epidermal growth factor receptor 2-positive gastric remnant cancer after bariatric surgery—case report
Rare case of human epidermal growth factor receptor 2-positive gastric remnant cancer after bariatric surgery—case report
Parallel to the increasing number of patients with obesity and metabolic syndrome, the number of bariatric procedures is r...
Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment of hormone-receptor-positive, human epider...
CRLF2 expression associated with poor outcome in Philadelphia-negative acute lymphoblastic leukemia
CRLF2 expression associated with poor outcome in Philadelphia-negative acute lymphoblastic leukemia
Adult Philadelphia (Ph)-negative B‑acute lymphoblastic leukemia (Ph-ALL) patients often exhibit elevated levels of C...
Biomarkers and treatment updates in renal cell carcinoma
Biomarkers and treatment updates in renal cell carcinoma
At this year’s ASCO Annual Meeting, researchers presented detailed findings concerning biomarkers and rare subtypes ...
ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer
ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer
Despite recent advances in therapy, certain subtypes of colorectal cancer, such as those that are microsatellite instabili...
ASCO 2023: highlights in breast cancer
ASCO 2023: highlights in breast cancer
The 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was again held in June 2023 in Chicag...
Cancer of unknown primary—state of the art
Cancer of unknown primary—state of the art
The Cancer of Unknown Primary (CUP) syndrome does not represent a single clinical entity but comprises a diverse group of ...
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
Implementation of targeted drugs in the treatment landscape of indolent B‑cell malignancies has facilitated long-ter...
Supportive management
Supportive management
The introduction of checkpoint inhibitor therapy and advances in targeted therapy...
Prostate cancer special—part 1
Prostate cancer special—part 1
Conflict of interest S.F. Shariat declares the following competing interes...
HER2 in focus—gastric cancer
HER2 in focus—gastric cancer
Conflict of interest A. Ilhan-Mutlu: Participation in advisory boards orga...
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
For the 2023 annual meeting of the American Society of Clinical Oncology (ASC...
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
The Wnt pathway is aberrantly activated in chronic lymphocytic leukemia (CLL) and contributes to the antiapoptotic and mit...
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna
Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...
A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer, September 9th-12th , hybrid congress
A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer, September 9th-12th , hybrid congress
Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...
Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study
Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study
To analyze the effectiveness of decitabine combined with low-dose Ara‑C, aclarubicin, and rhG-CSF (DCAG) as a&nb...
Genetic testing and management of prostate cancer patients with pathogenic germline variants
Genetic testing and management of prostate cancer patients with pathogenic germline variants
Prostate cancer (PCa) is an androgen-receptor signaling-dependent disease with a subset of patients harboring pat...
Management of malignant hypercalcemia in cancer patients—a short review
Management of malignant hypercalcemia in cancer patients—a short review
Hypercalcemia of malignancy (HCM) can be the first symptom leading to diagnosis and initiation of treatment in cancer pati...
Renal cell carcinoma
Renal cell carcinoma
Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for a...
Focal therapy in intermediate- and high-risk prostate cancer
Focal therapy in intermediate- and high-risk prostate cancer
Focal therapy is a treatment option for clinically localized prostate cancer, finding increased use in recent yea...
Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
In this short review, we aim to summarize the essential news and highlights in pancreatic cancer that were presented at AS...
Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment
Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment
In Europe, it is estimated that more than 65,000 men die each year from the consequences of advanced and metastatic prosta...
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
Evaluation of HER2 status and programmed death-ligand 1 (PD-L1) combined positive score (CPS) is mandatory in all...
ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma
ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma
Two exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that wil...
Renal crystal-storing histiocytosis successfully treated with bortezomib-based regimen
Renal crystal-storing histiocytosis successfully treated with bortezomib-based regimen
Crystal-storing histiocytosis (CSH) represents a rare disease seen in patients with monoclonal gammopathy of unkn...
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
There is an unmet need for the treatment of patients with HER2-positive gastroesophageal tumors whose disease progressed o...
Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis
Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis
Despite the increasing number of patients with metastatic pancreatic adenocarcinoma (mPDAC) receiving second-line chemothe...
Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer
Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer
This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus typ...
Load More
format_indent_increase